A dangerous strain of bird flu is spreading in US livestockMediaMedium/Alamy Since Donald Trump assumed office in January, the leading US public health agency has pulled back preparations for a potential bird flu pandemic. But as it steps back, another government agency is stepping up. While the US Department of Health and Human Services (HHS) previously held regular briefings on its efforts to prevent a wider outbreak of a deadly bird flu virus called H5N1 in people, it largely stopped once Trump took office. It has also cancelled funding for a vaccine that would have targeted the virus. In contrast, the US Department of Agriculture (USDA) has escalated its fight against H5N1’s spread in poultry flocks and dairy herds, including by funding the development of livestock vaccines. This particular virus – a strain of avian influenza called H5N1 – poses a significant threat to humans, having killed about half of the roughly 1000 people worldwide who tested positive for it since 2003. While the pathogen spreads rapidly in birds, it is poorly adapted to infecting humans and isn’t known to transmit between people. But that could change if it acquires mutations that allow it to spread more easily among mammals – a risk that increases with each mammalian infection. The possibility of H5N1 evolving to become more dangerous to people has grown significantly since March 2024, when the virus jumped from migratory birds to dairy cows in Texas. More than 1,070 herds across 17 states have been affected since then. H5N1 also infects poultry, placing the virus in closer proximity to people. Since 2022, nearly 175 million domestic birds have been culled in the US due to H5N1, and almost all of the 71 people who have tested positive for it had direct contact with livestock. Get the most essential health and fitness news in your inbox every Saturday. Sign up to newsletter “We need to take this seriously because when [H5N1] constantly is spreading, it’s constantly spilling over into humans,” says Seema Lakdawala at Emory University in Georgia. The virus has already killed a person in the US and a child in Mexico this year. Still, cases have declined under Trump. The last recorded human case was in February, and the number of affected poultry flocks fell 95 per cent between then and June. Outbreaks in dairy herds have also stabilised. It isn’t clear what is behind the decline. Lakdawala believes it is partly due to a lull in bird migration, which reduces opportunities for the virus to spread from wild birds to livestock. It may also reflect efforts by the USDA to contain outbreaks on farms. In February, the USDA unveiled a $1 billion plan for tackling H5N1, including strengthening farmers’ defences against the virus, such as through free biosecurity assessments. Of the 150 facilities that have undergone assessment, only one has experienced an H5N1 outbreak. Under Trump, the USDA also continued its National Milk Testing Strategy, which mandates farms provide raw milk samples for influenza testing. If a farm is positive for H5N1, it must allow the USDA to monitor livestock and implement measures to contain the virus. The USDA launched the programme in December and has since ramped up participation to 45 states. “The National Milk Testing Strategy is a fantastic system,” says Erin Sorrell at Johns Hopkins University in Maryland. Along with the USDA’s efforts to improve biosecurity measures on farms, milk testing is crucial for containing the outbreak, says Sorrell. But while the USDA has bolstered its efforts against H5N1, the HHS doesn’t appear to have followed suit. In fact, the recent drop in human cases may reflect decreased surveillance due to workforce cuts, says Sorrell. In April, the HHS laid off about 10,000 employees, including 90 per cent of staff at the National Institute for Occupational Safety and Health, an office that helps investigate H5N1 outbreaks in farm workers. “There is an old saying that if you don’t test for something, you can’t find it,” says Sorrell. Yet a spokesperson for the US Centers for Disease Control and Prevention (CDC) says its guidance and surveillance efforts have not changed. “State and local health departments continue to monitor for illness in persons exposed to sick animals,” they told New Scientist. “CDC remains committed to rapidly communicating information as needed about H5N1.” The USDA and HHS also diverge on vaccination. While the USDA has allocated $100 million toward developing vaccines and other solutions for preventing H5N1’s spread in livestock, the HHS cancelled $776 million in contracts for influenza vaccine development. The contracts – terminated on 28 May – were with the pharmaceutical company Moderna to develop vaccines targeting flu subtypes, including H5N1, that could cause future pandemics. The news came the same day Moderna reported nearly 98 per cent of the roughly 300 participants who received two doses of the H5 vaccine in a clinical trial had antibody levels believed to be protective against the virus. The US has about five million H5N1 vaccine doses stockpiled, but these are made using eggs and cultured cells, which take longer to produce than mRNA-based vaccines like Moderna’s. The Moderna vaccine would have modernised the stockpile and enabled the government to rapidly produce vaccines in the event of a pandemic, says Sorrell. “It seems like a very effective platform and would have positioned the US and others to be on good footing if and when we needed a vaccine for our general public,” she says. The HHS cancelled the contracts due to concerns about mRNA vaccines, which Robert F Kennedy Jr – the country’s highest-ranking public health official – has previously cast doubt on. “The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration,” said HHS communications director Andrew Nixon in a statement to New Scientist. However, mRNA technology isn’t new. It has been in development for more than half a century and numerous clinical trials have shown mRNA vaccines are safe. While they do carry the risk of side effects – the majority of which are mild – this is true of almost every medical treatment. In a press release, Moderna said it would explore alternative funding paths for the programme. “My stance is that we should not be looking to take anything off the table, and that includes any type of vaccine regimen,” says Lakdawala. “Vaccines are the most effective way to counter an infectious disease,” says Sorrell. “And so having that in your arsenal and ready to go just give you more options.” Topics:

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.Tech billionaires are making a risky bet with humanity’s future Sam Altman, Jeff Bezos, Elon Musk, and others may have slightly different goals, but their grand visions for the next decade and beyond are remarkably similar.They include aligning AI with the interests of humanity; creating an artificial superintelligence that will solve all the world’s most pressing problems; merging with that superintelligence to achieve immortality (or something close to it); establishing a permanent, self-­sustaining colony on Mars; and, ultimately, spreading out across the cosmos.Three features play a central role with powering these visions, says Adam Becker, a science writer and astrophysicist: an unshakable certainty that technology can solve any problem, a belief in the necessity of perpetual growth, and a quasi-religious obsession with transcending our physical and biological limits.In his timely new book, More Everything Forever: AI Overlords, Space Empires, and Silicon Valley’s Crusade to Control the Fate of Humanity, Becker reveals how these fantastical visions conceal a darker agenda. Read the full story. —Bryan Gardiner This story is from the next print edition of MIT Technology Review, which explores power—who has it, and who wants it. It’s set to go live on Wednesday June 25, so subscribe & save 25% to read it and get a copy of the issue when it lands! Here’s what food and drug regulation might look like under the Trump administration Earlier this week, two new leaders of the US Food and Drug Administration published a list of priorities for the agency. Both Marty Makary and Vinay Prasad are controversial figures in the science community. They were generally highly respected academics until the covid pandemic, when their contrarian opinions on masking, vaccines, and lockdowns turned many of their colleagues off them. Given all this, along with recent mass firings of FDA employees, lots of people were pretty anxious to see what this list might include—and what we might expect the future of food and drug regulation in the US to look like. So let’s dive into the pair’s plans for new investigations, speedy approvals, and the “unleashing” of AI. —Jessica Hamzelou This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here. The must-reads I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology. 1 NASA is investigating leaks on the ISSIt’s postponed launching private astronauts to the station while it evaluates. (WP $)+ Its core component has been springing small air leaks for months. (Reuters)+ Meanwhile, this Chinese probe is en route to a near-Earth asteroid. (Wired $) 2 Undocumented migrants are using social media to warn of ICE raidsThe DIY networks are anonymously reporting police presences across LA. (Wired $)+ Platforms’ relationships with protest activism has changed drastically. (NY Mag $)  3 Google’s AI Overviews is hallucinating about the fatal Air India crashIt incorrectly stated that it involved an Airbus plane, not a Boeing 787. (Ars Technica)+ Why Google’s AI Overviews gets things wrong. (MIT Technology Review) 4 Chinese engineers are sneaking suitcases of hard drives into the countryTo covertly train advanced AI models. (WSJ $)+ The US is cracking down on Huawei’s ability to produce chips. (Bloomberg $)+ What the US-China AI race overlooks. (Rest of World) 5 The National Hurricane Center is joining forces with DeepMindIt’s the first time the center has used AI to predict nature’s worst storms. (NYT $)+ Here’s what we know about hurricanes and climate change. (MIT Technology Review) 6 OpenAI is working on a product with toymaker MattelAI-powered Barbies?! (FT $)+ Nothing is safe from the creep of AI, not even playtime. (LA Times $)+ OpenAI has ambitions to reach billions of users. (Bloomberg $) 7 Chatbots posing as licensed therapists may be breaking the lawDigital rights organizations have filed a complaint to the FTC. (404 Media)+ How do you teach an AI model to give therapy? (MIT Technology Review) 8 Major companies are abandoning their climate commitmentsBut some experts argue this may not be entirely bad. (Bloomberg $)+ Google, Amazon and the problem with Big Tech’s climate claims. (MIT Technology Review) 9 Vibe coding is shaking up software engineeringEven though AI-generated code is inherently unreliable. (Wired $)+ What is vibe coding, exactly? (MIT Technology Review) 10 TikTok really loves hotdogs And who can blame it? (Insider $) Quote of the day “It kind of jams two years of work into two months.” —Andrew Butcher, president of the Maine Connectivity Authority, tells Ars Technica why it’s so difficult to meet the Trump administration’s new plans to increase broadband access in certain states. One more thing The surprising barrier that keeps us from building the housing we needIt’s a tough time to try and buy a home in America. From the beginning of the pandemic to early 2024, US home prices rose by 47%. In large swaths of the country, buying a home is no longer a possibility even for those with middle-class incomes. For many, that marks the end of an American dream built around owning a house. Over the same time, rents have gone up 26%.The reason for the current rise in the cost of housing is clear to most economists: a lack of supply. Simply put, we don’t build enough houses and apartments, and we haven’t for years. But the reality is that even if we ease the endless permitting delays and begin cutting red tape, we will still be faced with a distressing fact: The construction industry is not very efficient when it comes to building stuff. Read the full story. —David Rotman We can still have nice things A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line or skeet ’em at me.) + If you’re one of the unlucky people who has triskaidekaphobia, look away now.+ 15-year old Nicholas is preparing to head from his home in the UK to Japan to become a professional sumo wrestler.+ Earlier this week, London played host to 20,000 women in bald caps. But why? ($)+ Why do dads watch TV standing up? I need to know.

On November 4, 2003, a doctor gave Jon Gluck some of the worst news imaginable: He had cancer — one that later tests would reveal as multiple myeloma, a severe blood and bone marrow cancer. Jon was told he might have as little as 18 months to live. He was 38, a thriving magazine editor in New York with a 7-month-old daughter whose third birthday, he suddenly realized, he might never see.“The moment after I was told I had cancer, I just said ‘no, no, no,’” Jon told me in an interview just last week. “This cannot be true.”Living in remissionThe fact that Jon is still here, talking to me in 2025, tells you that things didn’t go the way the medical data would have predicted on that November morning. He has lived with his cancer, through waves of remission and recurrence, for more than 20 years, an experience he chronicles with grace and wit in his new book An Exercise in Uncertainty. That 7-month-old daughter is now in college.RelatedWhy do so many young people suddenly have cancer?You could say Jon has beaten the odds, and he’s well aware that chance played some role in his survival. (“Did you know that ‘Glück’ is German for ‘luck’?” he writes in the book, noting his good fortune that a random spill on the ice is what sent him to the doctor in the first place, enabling them to catch his cancer early.) Cancer is still a terrible health threat, one that is responsible for 1 in 6 deaths around the world, killing nearly 10 million people a year globally and over 600,000 people a year in the US. But Jon’s story and his survival demonstrate something that is too often missed: We’ve turned the tide in the war against cancer. The age-adjusted death rate in the US for cancer has declined by about a third since 1991, meaning people of a given age have about a third lower risk of dying from cancer than people of the same age more than three decades ago. That adds up to over 4 million fewer cancer deaths over that time period. Thanks to breakthroughs in treatments like autologous stem-cell harvesting and CAR-T therapy — breakthroughs Jon himself benefited from, often just in time — cancer isn’t the death sentence it once was.Our World in DataGetting better all the timeThere’s no doubt that just as the rise of smoking in the 20th century led to a major increase in cancer deaths, the equally sharp decline of tobacco use eventually led to a delayed decrease. Smoking is one of the most potent carcinogens in the world, and at the peak in the early 1960s, around 12 cigarettes were being sold per adult per day in the US. Take away the cigarettes and — after a delay of a couple of decades — lung cancer deaths drop in turn along with other non-cancer smoking-related deaths.But as Saloni Dattani wrote in a great piece earlier this year, even before the decline of smoking, death rates from non-lung cancers in the stomach and colon had begun to fall. Just as notably, death rates for childhood cancers — which for obvious reasons are not connected to smoking and tend to be caused by genetic mutations — have fallen significantly as well, declining sixfold since 1950. In the 1960s, for example, only around 10 percent of children diagnosed with acute lymphoblastic leukemia survived more than five years. Today it’s more than 90 percent. And the five-year survival rate for all cancers has risen from 49 percent in the mid-1970s to 69 percent in 2019. We’ve made strikes against the toughest of cancers, like Jon’s multiple myeloma. Around when Jon was diagnosed, the five-year survival rate was just 34 percent. Today it’s as high as 62 percent, and more and more people like Jon are living for decades. “There has been a revolution in cancer survival,” Jon told me. “Some illnesses now have far more successful therapies than others, but the gains are real.”Three cancer revolutions The dramatic bend in the curve of cancer deaths didn’t happen by accident — it’s the compound interest of three revolutions.While anti-smoking policy has been the single biggest lifesaver, other interventions have helped reduce people’s cancer risk. One of the biggest successes is the HPV vaccine. A study last year found that death rates of cervical cancer — which can be caused by HPV infections — in US women ages 20–39 had dropped 62 percent from 2012 to 2021, thanks largely to the spread of the vaccine. Other cancers have been linked to infections, and there is strong research indicating that vaccination can have positive effects on reducing cancer incidence. The next revolution is better and earlier screening. It’s generally true that the earlier cancer is caught, the better the chances of survival, as Jon’s own story shows. According to one study, incidences of late-stage colorectal cancer in Americans over 50 declined by a third between 2000 and 2010 in large part because rates of colonoscopies almost tripled in that same time period. And newer screening methods, often employing AI or using blood-based tests, could make preliminary screening simpler, less invasive and therefore more readily available. If 20th-century screening was about finding physical evidence of something wrong — the lump in the breast — 21st-century screening aims to find cancer before symptoms even arise.Most exciting of all are frontier developments in treating cancer, much of which can be tracked through Jon’s own experience. From drugs like lenalidomide and bortezomib in the 2000s, which helped double median myeloma survival, to the spread of monoclonal antibodies, real breakthroughs in treatments have meaningfully extended people’s lives — not just by months, but years.Perhaps the most promising development is CAR-T therapy, a form of immunotherapy. Rather than attempting to kill the cancer directly, immunotherapies turn a patient’s own T-cells into guided missiles. In a recent study of 97 patients with multiple myeloma, many of whom were facing hospice care, a third of those who received CAR-T therapy had no detectable cancer five years later. It was the kind of result that doctors rarely see. “CAR-T is mind-blowing — very science-fiction futuristic,” Jon told me. He underwent his own course of treatment with it in mid-2023 and writes that the experience, which put his cancer into a remission he’s still in, left him feeling “physically and metaphysically new.”A welcome uncertaintyWhile there are still more battles to be won in the war on cancer, and there are certain areas — like the rising rates of gastrointestinal cancers among younger people — where the story isn’t getting better, the future of cancer treatment is improving. For cancer patients like Jon, that can mean a new challenge — enduring the essential uncertainty that comes with living under a disease that’s controllable but which could always come back. But it sure beats the alternative.“I’ve come to trust so completely in my doctors and in these new developments,” he said. “I try to remain cautiously optimistic that my future will be much like the last 20 years.” And that’s more than he or anyone else could have hoped for nearly 22 years ago. A version of this story originally appeared in the Good News newsletter. Sign up here!See More: Health